• About
  • Team
    • Management
    • Board
  • Lead Candidate
  • Investors
    • Investor Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Governance Documents
      • Board of Directors
      • Board Committees
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • SEC Filings
      • Insider Transactions
    • Investor Resources
      • Investor Alerts
      • Information Request
  • Publications
  • Careers
  • Contact

Join our mailing list and stay abreast of our progress!

Subscribe Now
© 2021 Satsuma Pharmaceuticals, Inc. 
All rights reserved.
  • About
  • Team
    • Management
    • Board
  • Lead Candidate
  • Investors
    • Investor Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Governance Documents
      • Board of Directors
      • Board Committees
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • SEC Filings
      • Insider Transactions
    • Investor Resources
      • Investor Alerts
      • Information Request
  • Publications
  • Careers
  • Contact

News

September 3, 2019
 
Read More »

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock

September 3, 2019
 
Read More »

Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress

August 22, 2019
 
Read More »

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

July 8, 2019
 
Read More »

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society’s Annual Scientific Meeting

May 29, 2019
 
Read More »

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

April 24, 2019
 
Read More »

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

April 1, 2019
 
Read More »

Satsuma Pharmaceuticals to Present at Needham & Company 18th Annual Healthcare Conference

February 20, 2019
 
Read More »

Satsuma Pharmaceuticals Provides Corporate Update and Prepares to Advance Lead Product Candidate, STS101, Into Phase 3 Efficacy Trial for Acute Migraine

February 14, 2019
 
Read More »

Satsuma Pharmaceuticals Announces Presentations at Upcoming Investor Conferences

January 5, 2017
 
Read More »

Satsuma Pharmaceuticals Spins Out from Shin Nippon Biomedical Laboratories (SNBL) with Funding from Leading Institutional Life Science Investors

MENU
  • About
  • Team
    • Management
    • Board
  • Lead Candidate
  • Investors
    • Investor Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Governance Documents
      • Board of Directors
      • Board Committees
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • SEC Filings
      • Insider Transactions
    • Investor Resources
      • Investor Alerts
      • Information Request
  • Publications
  • Careers
  • Contact